U.S. Vaccines Market (2026 - 2033) Size, Share & Trends Analysis Report By Indication (Viral, Bacterial, Cancer Vaccines, Allergy), By Type (Subunit, Inactivated), By Payer Type, By Age Group, By Use Populations, By Usage/Administration Pattern, By Sales, And Segment Forecasts

Table of Contents

Chapter 1. Methodology and Scope
                    1.1. Market Segmentation & Scope
                    1.2. Segment Definitions
                        1.2.1. Indication
                        1.2.2. Type
                        1.2.3. Payer Type
                        1.2.4. Age Group
                        1.2.5. Use Populations
                        1.2.6. Usage/Administration Pattern
                        1.2.7. Sales
                    1.3. Estimates and Forecast Timeline
                    1.4. Research Methodology
                    1.5. Information Procurement
                        1.5.1. Purchased Database
                        1.5.2. GVR’s Internal Database
                        1.5.3. Secondary Sources
                        1.5.4. Primary Research
                    1.6. Information Analysis
                        1.6.1. Data Analysis Models
                    1.7. Market Formulation & Data Visualization
                    1.8. Model Details
                        1.8.1. Commodity Flow Analysis
                    1.9. List of Secondary Sources
                    1.10. Objectives
Chapter 2. Executive Summary
                    2.1. Market Snapshot
                    2.2. Segment Snapshot
                    2.3. Competitive Landscape Snapshot
Chapter 3. U.S. Vaccines Market Variables, Trends, & Scope
                    3.1. Market Lineage Outlook
                    3.2. Market Dynamics
                        3.2.1. Market Driver Analysis
                        3.2.2. Market Restraint Analysis
                    3.3. Business Environment Analysis
                        3.3.1. Industry Analysis - Porter’s Five Forces Analysis
                            3.3.1.1. Supplier Power
                            3.3.1.2. Buyer Power
                            3.3.1.3. Substitution Threat
                            3.3.1.4. Threat of New Entrants
                            3.3.1.5. Competitive Rivalry
                        3.3.2. PESTLE Analysis
                        3.3.3. Pipeline Analysis
                        3.3.4. Patent Expiry Analysis
                        3.3.5. Pricing Analysis
Chapter 4. U.S. Vaccine Market - Market Entry & Regulatory Landscape
                    4.1. Regulatory Framework for Vaccines in the U.S.: CBER vs. CDER
                    4.2. Vaccine Approval Pathway in the U.S. (IND → BLA → GMP → Lot Consistency Trials)
                        4.2.1. Preclinical Development and IND Submission
                        4.2.2. Clinical Development Phases
                        4.2.3. Biologics License Application (BLA)
                        4.2.4. GMP Compliance and Manufacturing Validation
                        4.2.5. Lot Consistency Trials and Lot Release
                    4.3. Conditional Approvals, Accelerated Pathways, and Phase IV Requirements
                        4.3.1. Accelerated Approval and Priority Review
                        4.3.2. Emergency Use Authorization (EUA)
                        4.3.3. Phase IV Post-Marketing Requirements
                        4.3.4. Pharmacovigilance and Safety Monitoring
                    4.4. Clinical Trial Strategy for U.S. Vaccine Market Entry
                        4.4.1. FDA Expectations for Vaccine Trials
                        4.4.2. Ethnic and Demographic Representation
                        4.4.3. State-Level Enrollment Feasibility
                        4.4.4. Impact of U.S. Immunization Policy on Trial Design
                        4.4.5. Market Entry Strategy
                    4.5. Key Implications for Market Entry in the U.S. Vaccine Market
                    4.6. Analyst Perspective & Key Opinion Leader (KOL) Insights
Chapter 5. U.S. Vaccine Market - Product Usage & Recommendations
                    5.1. Role of the Advisory Committee on Immunization Practices (ACIP)
                        5.1.1. ACIP Composition And Structure
                        5.1.2. Meeting Process And Decision Framework
                        5.1.3. Influence On Market Adoption
                    5.2. Adoption of ACIP Recommendations Across Providers, Payers, and States
                        5.2.1. Provider Adoption
                        5.2.2. Payer Adoption
                        5.2.3. State-Level Variation
                        5.2.4. Adoption Timeline Pattern
                    5.3. Reimbursement Dynamics in the U.S. Vaccine Market
                        5.3.1. Public Programs
                        5.3.2. Private Insurance Coverage
                        5.3.3. Out-Of-Pocket Costs
                    5.4. Mandatory Vaccination Requirements in the United States
                        5.4.1. School Entry Requirements
                        5.4.2. Workplace Requirements
                        5.4.3. Vaccination Recommendations For Elderly Populations
                        5.4.4. State-Level Policy Differences
                    5.5. Market Impact of Product Usage Policies
                    5.6. Analyst Perspective & Key Opinion Leader Insights
                        5.6.1. Role Of The Advisory Committee On Immunization Practices (ACIP)
                            5.6.1.1. Analyst Perspective
                        5.6.2. Adoption Of ACIP Recommendations Across Providers, Payers, And States
                            5.6.2.1. Analyst Perspective
                        5.6.3. Reimbursement Dynamics In The U.S. Vaccine Market
                            5.6.3.1. Analyst Perspective
                        5.6.4. Mandatory Vaccination Requirements In The United States
                            5.6.4.1. Analyst Perspective
                        5.6.5. Implications For Vaccine Market Uptake
Chapter 6. U.S. Vaccine Market - Pharmacovigilance & Legal Framework
                    6.1. Post-marketing safety monitoring
                        6.1.1. Government Requirements
                        6.1.2. Adverse Event Reporting
                        6.1.3. Recall Process
                        6.1.4. Case Study Evaluation: Historical And Recent Safety Actions
                    6.2. Legal considerations
                        6.2.1. Manufacturer Vs. Distributor Responsibilities
                        6.2.2. Liability Exposure
                    6.3. Role of the National Vaccine Injury Compensation
                    6.4. Analyst Perspective & Key Opinion Leader Insights
Chapter 7. U.S. Vaccines Market: Indication Business Analysis
                    7.1. Indication Market Share, 2025 & 2033
                    7.2. Indication Segment Dashboard
                    7.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Million)
                    7.4. Viral Vaccines
                        7.4.1. Viral Vaccines Market, 2021 - 2033 (USD Million)
                        7.4.2. Hepatitis
                            7.4.2.1. Hepatitis Market, 2021 - 2033 (USD Million)
                        7.4.3. Influenza
                            7.4.3.1. Influenza Market, 2021 - 2033 (USD Million)
                        7.4.4. HPV
                            7.4.4.1. HPV Market, 2021 - 2033 (USD Million)
                        7.4.5. MMR
                            7.4.5.1. MMR Market, 2021 - 2033 (USD Million)
                        7.4.6. Rotavirus
                            7.4.6.1. Rotavirus Market, 2021 - 2033 (USD Million)
                        7.4.7. Herpes Zoster
                            7.4.7.1. Herpes Zoster Market, 2021 - 2033 (USD Million)
                        7.4.8. Japanese Encephalitis
                            7.4.8.1. Japanese Encephalitis Market, 2021 - 2033 (USD Million)
                        7.4.9. RSV
                            7.4.9.1. RSV Market, 2021 - 2033 (USD Million)
                        7.4.10. Others
                            7.4.10.1. Others Market, 2021 - 2033 (USD Million)
                    7.5. Bacterial Vaccines
                        7.5.1. Bacterial Vaccines Market, 2021 - 2033 (USD Million)
                        7.5.2. Meningococcal Diseases
                            7.5.2.1. Meningococcal Diseases Market, 2021 - 2033 (USD Million)
                        7.5.3. Pneumococcal Diseases
                            7.5.3.1. Pneumococcal Diseases Market, 2021 - 2033 (USD Million)
                        7.5.4. DPT
                            7.5.4.1. DPT Market, 2021 - 2033 (USD Million)
                        7.5.5. Others
                            7.5.5.1. Others Market, 2021 - 2033 (USD Million)
                    7.6. Cancer Vaccines
                        7.6.1. Cancer Vaccines Market, 2021 - 2033 (USD Million)
                    7.7. Allergy Vaccines
                        7.7.1. Allergy Vaccines Market, 2021 - 2033 (USD Million)
                    7.8. Others
                        7.8.1. Others Market, 2021 - 2033 (USD Million)
Chapter 8. U.S. Vaccines Market: Type Business Analysis
                    8.1. Type Market Share, 2025 & 2033
                    8.2. Type Segment Dashboard
                    8.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Million)
                    8.4. Subunit Vaccines
                        8.4.1. Subunit Vaccines Market, 2021 - 2033 (USD Million)
                        8.4.2. Recombinant Vaccines
                            8.4.2.1. Recombinant Vaccines Market, 2021 - 2033 (USD Million)
                        8.4.3. Conjugate Vaccines
                            8.4.3.1. Conjugate Vaccines Market, 2021 - 2033 (USD Million)
                        8.4.4. Toxoid Vaccines
                            8.4.4.1. Toxoid Vaccines Market, 2021 - 2033 (USD Million)
                    8.5. Inactivated
                        8.5.1. Inactivated Market, 2021 - 2033 (USD Million)
                    8.6. Live Attenuated
                        8.6.1. Live Attenuated Market, 2021 - 2033 (USD Million)
                    8.7. mRNA Vaccines
                        8.7.1. mRNA Vaccines Market, 2021 - 2033 (USD Million)
                    8.8. Viral Vector Vaccines
                        8.8.1. Viral Vector Vaccines Market, 2021 - 2033 (USD Million)
Chapter 9. U.S. Vaccines Market: Payer Type Business Analysis
                    9.1. Payer Type Market Share, 2025 & 2033
                    9.2. Payer Type Segment Dashboard
                    9.3. Market Size & Forecasts and Trend Analysis, by Payer type, 2021 to 2033 (USD Million)
                    9.4. Public Payer
                        9.4.1. Public Payer Market, 2021 - 2033 (USD Million)
                        9.4.2. Medicare
                            9.4.2.1. Medicare Market, 2021 - 2033 (USD Million)
                        9.4.3. Medicaid
                            9.4.3.1. Medicaid Market, 2021 - 2033 (USD Million)
                        9.4.4. Federal Programs
                            9.4.4.1. Federal Programs Market, 2021 - 2033 (USD Million)
                    9.5. Private Payers
                        9.5.1. Private Payers Market, 2021 - 2033 (USD Million)
                        9.5.2. Commercial Insurance Plans
                            9.5.2.1. Commercial Insurance Plans Market, 2021 - 2033 (USD Million)
                        9.5.3. Workplace Programs
                            9.5.3.1. Workplace Programs Market, 2021 - 2033 (USD Million)
                    9.6. Out-of-Pocket / Self-Pay
                        9.6.1. Out-of-Pocket / Self-Pay Market, 2021 - 2033 (USD Million)
                    9.7. Others
                        9.7.1. Others Market, 2021 - 2033 (USD Million)
Chapter 10. U.S. Vaccines Market: Age Group Business Analysis
                    10.1. Age Group Market Share, 2025 & 2033
                    10.2. Age Group Segment Dashboard
                    10.3. Market Size & Forecasts and Trend Analysis, by Age Group, 2021 to 2033 (USD Million)
                    10.4. Pediatrics (0-17 years)
                        10.4.1. Pediatrics (0-17 years) Market, 2021 - 2033 (USD Million)
                    10.5. Adults (18-64 years)
                        10.5.1. Adults (18-64 years) Market, 2021 - 2033 (USD Million)
                    10.6. Elderly (65+ years)
                        10.6.1. Elderly (65+ years) Market, 2021 - 2033 (USD Million)
Chapter 11. U.S. Vaccines Market: Use Populations Business Analysis
                    11.1. Use Populations Market Share, 2025 & 2033
                    11.2. Use Populations Segment Dashboard
                    11.3. Market Size & Forecasts and Trend Analysis, by Use Populations, 2021 to 2033 (USD Million)
                    11.4. Workplace
                        11.4.1. Workplace Market, 2021 - 2033 (USD Million)
                    11.5. Schools
                        11.5.1. Schools Market, 2021 - 2033 (USD Million)
                    11.6. Travelers
                        11.6.1. Travelers Market, 2021 - 2033 (USD Million)
                    11.7. Military & Special Occupations
                        11.7.1. Military & Special Occupations Market, 2021 - 2033 (USD Million)
                    11.8. Others
                        11.8.1. Others Market, 2021 - 2033 (USD Million)
Chapter 12. U.S. Vaccines Market: Usage/Administration Pattern Business Analysis
                    12.1. Usage/Administration Pattern Market Share, 2025 & 2033
                    12.2. Usage/Administration Pattern Segment Dashboard
                    12.3. Market Size & Forecasts and Trend Analysis, by Usage/Administration Pattern, 2021 to 2033 (USD Million)
                    12.4. Seasonal Vaccines
                        12.4.1. Seasonal Vaccines Market, 2021 - 2033 (USD Million)
                    12.5. Year-Round Vaccines
                        12.5.1. Year-Round Vaccines Market, 2021 - 2033 (USD Million)
                    12.6. Others
                        12.6.1. Others Market, 2021 - 2033 (USD Million)
Chapter 13. U.S. Vaccines Market: Sales Business Analysis
                    13.1. Sales Market Share, 2025 & 2033
                    13.2. Sales Segment Dashboard
                    13.3. Market Size & Forecasts and Trend Analysis, by Sales, 2021 to 2033 (USD Million)
                    13.4. Tender-Based
                        13.4.1. Tender-Based Market, 2021 - 2033 (USD Million)
                    13.5. Direct Sales to Providers
                        13.5.1. Direct Sales to Providers Market, 2021 - 2033 (USD Million)
Chapter 14. Competitive Landscape
                    14.1. Participant Overview
                    14.2. Company Market Position Analysis
                    14.3. Company Categorization
                    14.4. Strategy Mapping
                    14.5. Company Profiles/Listing
                        14.5.1. Pfizer
                            14.5.1.1. Overview
                            14.5.1.2. Financial Performance
                            14.5.1.3. Product Benchmarking
                            14.5.1.4. Strategic Initiatives
                        14.5.2. GSK
                            14.5.2.1. Overview
                            14.5.2.2. Financial Performance
                            14.5.2.3. Product Benchmarking
                            14.5.2.4. Strategic Initiatives
                        14.5.3. Merck & Co. (MSD)
                            14.5.3.1. Overview
                            14.5.3.2. Financial Performance
                            14.5.3.3. Product Benchmarking
                            14.5.3.4. Strategic Initiatives
                        14.5.4. Sanofi
                            14.5.4.1. Overview
                            14.5.4.2. Financial Performance
                            14.5.4.3. Product Benchmarking
                            14.5.4.4. Strategic Initiatives
                        14.5.5. Moderna
                            14.5.5.1. Overview
                            14.5.5.2. Financial Performance
                            14.5.5.3. Product Benchmarking
                            14.5.5.4. Strategic Initiatives
                        14.5.6. Novavax
                            14.5.6.1. Overview
                            14.5.6.2. Financial Performance
                            14.5.6.3. Product Benchmarking
                            14.5.6.4. Strategic Initiatives
                        14.5.7. CSL Limited
                            14.5.7.1. Overview
                            14.5.7.2. Financial Performance
                            14.5.7.3. Product Benchmarking
                            14.5.7.4. Strategic Initiatives
                        14.5.8. AstraZeneca
                            14.5.8.1. Overview
                            14.5.8.2. Financial Performance
                            14.5.8.3. Product Benchmarking
                            14.5.8.4. Strategic Initiatives
                        14.5.9. Serum Institute of India
                            14.5.9.1. Overview
                            14.5.9.2. Financial Performance
                            14.5.9.3. Product Benchmarking
                            14.5.9.4. Strategic Initiatives

List of Tables

Table 1. List of secondary sources
Table 2. List of abbreviations
Table 3. U.S. vaccines market, by indication, 2021 - 2033 (USD Million)
Table 4. U.S. vaccines market, by type, 2021 - 2033 (USD Million)
Table 5. U.S. vaccines market, by payer type, 2021 - 2033 (USD Million)
Table 6. U.S. vaccines market, by age group, 2021 - 2033 (USD Million)
Table 7. U.S. vaccines market, by use populations, 2021 - 2033 (USD Million)
Table 8. U.S. vaccines market, by usage/administration pattern, 2021 - 2033 (USD Million)
Table 9. U.S. vaccines market, by sales, 2021 - 2033

List of Figures

Fig. 1 U.S. vaccines market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Competitive landscape
Fig. 10 U.S. vaccines market dynamics
Fig. 11 U.S. vaccines market: Porter’s five forces analysis
Fig. 12 U.S. vaccines market: PESTLE analysis
Fig. 13 Indication market, 2021 - 2033 (USD Million)
Fig. 14 Viral Vaccines market, 2021 - 2033 (USD Million)
Fig. 15 Hepatitis market, 2021 - 2033 (USD Million)
Fig. 16 Influenza market, 2021 - 2033 (USD Million)
Fig. 17 HPV market, 2021 - 2033 (USD Million)
Fig. 18 MMR market, 2021 - 2033 (USD Million)
Fig. 19 Rotavirus market, 2021 - 2033 (USD Million)
Fig. 20 Herpes Zoster market, 2021 - 2033 (USD Million)
Fig. 21 Japanese Encephalitis market, 2021 - 2033 (USD Million)
Fig. 22 RSV market, 2021 - 2033 (USD Million)
Fig. 23 Others market, 2021 - 2033 (USD Million)
Fig. 24 Bacterial Vaccines market, 2021 - 2033 (USD Million)
Fig. 25 Meningococcal Diseases market, 2021 - 2033 (USD Million)
Fig. 26 Pneumococcal Diseases market, 2021 - 2033 (USD Million)
Fig. 27 DPT market, 2021 - 2033 (USD Million)
Fig. 28 Others market, 2021 - 2033 (USD Million)
Fig. 29 Cancer Vaccines market, 2021 - 2033 (USD Million)
Fig. 30 Allergy Vaccines market, 2021 - 2033 (USD Million)
Fig. 31 Others market, 2021 - 2033 (USD Million)
Fig. 32 Type market, 2021 - 2033 (USD Million)
Fig. 33 Subunit Vaccines market, 2021 - 2033 (USD Million)
Fig. 34 Recombinant Vaccines market, 2021 - 2033 (USD Million)
Fig. 35 Conjugate Vaccines market, 2021 - 2033 (USD Million)
Fig. 36 Toxoid Vaccines market, 2021 - 2033 (USD Million)
Fig. 37 Inactivated market, 2021 - 2033 (USD Million)
Fig. 38 Live Attenuated market, 2021 - 2033 (USD Million)
Fig. 39 mRNA Vaccines market, 2021 - 2033 (USD Million)
Fig. 40 Viral Vector Vaccines market, 2021 - 2033 (USD Million)
Fig. 41 Payer Type market, 2021 - 2033 (USD Million)
Fig. 42 Public Payer market, 2021 - 2033 (USD Million)
Fig. 43 Medicare market, 2021 - 2033 (USD Million)
Fig. 44 Medicaid market, 2021 - 2033 (USD Million)
Fig. 45 Federal Programs market, 2021 - 2033 (USD Million)
Fig. 46 Private Payers market, 2021 - 2033 (USD Million)
Fig. 47 Commercial Insurance Plans market, 2021 - 2033 (USD Million)
Fig. 48 Workplace Programs market, 2021 - 2033 (USD Million)
Fig. 49 Out-of-Pocket / Self-Pay market, 2021 - 2033 (USD Million)
Fig. 50 Others market, 2021 - 2033 (USD Million)
Fig. 51 Age Group market, 2021 - 2033 (USD Million)
Fig. 52 Pediatrics (0-17 years) market, 2021 - 2033 (USD Million)
Fig. 53 Adults (18-64 years) market, 2021 - 2033 (USD Million)
Fig. 54 Elderly (65+ years) market, 2021 - 2033 (USD Million)
Fig. 55 Use Populations market, 2021 - 2033 (USD Million)
Fig. 56 Workplace market, 2021 - 2033 (USD Million)
Fig. 57 Schools market, 2021 - 2033 (USD Million)
Fig. 58 Travelers market, 2021 - 2033 (USD Million)
Fig. 59 Military & Special Occupations market, 2021 - 2033 (USD Million)
Fig. 60 Others market, 2021 - 2033 (USD Million)
Fig. 61 Usage/Administration Pattern market, 2021 - 2033 (USD Million)
Fig. 62 Seasonal Vaccines market, 2021 - 2033 (USD Million)
Fig. 63 Year-Round Vaccines market, 2021 - 2033 (USD Million)
Fig. 64 Others market, 2021 - 2033 (USD Million)
Fig. 65 Sales market, 2021 - 2033 (USD Million)
Fig. 66 Tender-Based market, 2021 - 2033 (USD Million)
Fig. 67 Direct Sales to Providers market, 2021 - 2033 (USD Million)
Fig. 68 Company categorization
Fig. 69 Company market position analysis
Fig. 70 Strategic framework